ZA983720B - Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy. - Google Patents

Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy.

Info

Publication number: ZA983720B
Authority: ZA; South Africa
Prior art keywords: preventing; aldose reductase; diabetic cardiomyopathy; reductase inhibition; reversing diabetic
Prior art date: 1997-05-05

Application number

ZA9803720A

Other languages

English (en)

Inventor

Brian Frank Johnson

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-05

Filing date

1998-05-04

Publication date

1999-11-04

1998-05-04 Application filed by Pfizer filed Critical Pfizer

1999-11-04 Publication of ZA983720B publication Critical patent/ZA983720B/xx

Links

208000032781 Diabetic cardiomyopathy Diseases 0.000 title abstract 2
102000016912 Aldehyde Reductase Human genes 0.000 title 1
108010053754 Aldehyde reductase Proteins 0.000 title 1
230000005764 inhibitory process Effects 0.000 title 1
239000003288 aldose reductase inhibitor Substances 0.000 abstract 1
229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA9803720A 1997-05-05 1998-05-04 Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy. ZA983720B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US4582297P	1997-05-05	1997-05-05

Publications (1)

Publication Number	Publication Date
ZA983720B true ZA983720B (en)	1999-11-04

Family

ID=21940071

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA9803720A ZA983720B (en)	1997-05-05	1998-05-04	Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy.

Country Status (17)

Country	Link
US (1)	US5990111A (de)
EP (1)	EP0880964B1 (de)
JP (1)	JP3010153B2 (de)
KR (1)	KR19980086748A (de)
AT (1)	ATE277607T1 (de)
AU (1)	AU725621B2 (de)
CA (1)	CA2236553C (de)
DE (1)	DE69826561T2 (de)
DK (1)	DK0880964T3 (de)
ES (1)	ES2227773T3 (de)
HU (1)	HUP9801022A3 (de)
IL (1)	IL124236A (de)
MY (1)	MY136261A (de)
NZ (1)	NZ330359A (de)
PT (1)	PT880964E (de)
TW (1)	TW589184B (de)
ZA (1)	ZA983720B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6413965B1 (en) *	1999-06-30	2002-07-02	Pfizer Inc.	Compositions and treatment for diabetic complications
US6426341B1 (en) *	1999-06-30	2002-07-30	Pfizer Inc.	Treatment for diabetic complications
US6555540B1 (en) *	1999-06-30	2003-04-29	Pfizer Inc	Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
CA2382228A1 (en) *	1999-08-23	2001-03-01	University Of Virginia Patent Foundation	Method and apparatus for predicting the risk of hypoglycemia
EP1106210A3 (de) *	1999-12-07	2003-12-03	Pfizer Products Inc.	Zusammensetzungen, für die Behandlung von diabetischen Komplikationen, welche Aldosereductasehemmern und antihypertensive Mitteln enthalten
US6380200B1 (en) *	1999-12-07	2002-04-30	Pfizer, Inc.	Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
CO5271699A1 (es)	2000-01-24	2003-04-30	Pfizer Prod Inc	Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US20050239063A1 (en) *	2001-03-30	2005-10-27	Lee Shao C	Determination of risk factors for cataract by aldose reductase genotype
WO2003105864A1 (en) *	2002-06-13	2003-12-24	Board Of Regents, The University Of Texas System	Methods and compositions involving aldose reductase inhibitors
US20110092566A1 (en) *	2004-11-19	2011-04-21	Srivastava Satish K	Treatment of cancer with aldose reductase inhibitors
US8273746B2 (en) *	2007-03-23	2012-09-25	The Board Of Regents Of The University Of Texas System	Methods involving aldose reductase inhibitors
US20090270490A1 (en) *	2008-04-24	2009-10-29	The Board Of Regents Of The University Of Texas System	Methods involving aldose reductase inhibition
CA2822672C (en)	2010-12-23	2018-06-05	The Board Of Regents Of The University Of Texas System	Methods for treating copd

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4939140A (en) *	1985-11-07	1990-07-03	Pfizer Inc.	Heterocyclic oxophthalazinyl acetic acids
ES2032749T3 (es) *	1985-11-07	1993-03-01	Pfizer Inc.	Acidos oxoftalazinil-aceticos heterociclicos.
US4748280A (en) *	1985-11-07	1988-05-31	Pfizer Inc.	Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6)
US4743611A (en) *	1986-07-02	1988-05-10	American Home Products Corp.	Naphthalenylsulfonylimidazolidinediones and their thioxo analogs useful as aldose reductase inhibitors
US4868301A (en) *	1987-06-09	1989-09-19	Pfizer Inc.	Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
JPH0676391B2 (ja) *	1987-06-09	1994-09-28	フアイザー・インコーポレイテツド	ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
EP0322153A3 (de) *	1987-12-21	1990-08-16	Pfizer Inc.	Heterozyklyl Oxophtalazynyl-Essigsäuren
US4954629A (en) *	1989-05-11	1990-09-04	Pfizer Inc.	Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
US5164391A (en) *	1989-09-20	1992-11-17	Sanwa Kagaku Kenkyusho Co., Ltd.	Hydantoin derivatives for treating complications of diabetes and circulatory diseases
WO1991009019A1 (en) *	1989-12-15	1991-06-27	Pfizer Inc.	Substituted oxophthalazinyl acetic acids and analogs thereof
US5064830A (en) *	1990-08-02	1991-11-12	Pfizer Inc.	Lowering of blood uric acid levels
US5728704A (en) *	1992-09-28	1998-03-17	Pfizer Inc.	Substituted pyridmidines for control of diabetic complications
US5391551A (en) *	1993-05-10	1995-02-21	Pfizer Inc.	Method of lowering blood lipid levels
US5834466A (en) *	1994-12-22	1998-11-10	The Regents Of The University Of California	Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia

1998
- 1998-04-27 IL IL12423698A patent/IL124236A/xx not_active IP Right Cessation
- 1998-04-30 TW TW087106684A patent/TW589184B/zh not_active IP Right Cessation
- 1998-05-01 CA CA002236553A patent/CA2236553C/en not_active Expired - Fee Related
- 1998-05-01 EP EP98303447A patent/EP0880964B1/de not_active Expired - Lifetime
- 1998-05-01 ES ES98303447T patent/ES2227773T3/es not_active Expired - Lifetime
- 1998-05-01 AT AT98303447T patent/ATE277607T1/de not_active IP Right Cessation
- 1998-05-01 PT PT98303447T patent/PT880964E/pt unknown
- 1998-05-01 DE DE69826561T patent/DE69826561T2/de not_active Expired - Fee Related
- 1998-05-01 US US09/071,589 patent/US5990111A/en not_active Expired - Fee Related
- 1998-05-01 DK DK98303447T patent/DK0880964T3/da active
- 1998-05-04 KR KR1019980015947A patent/KR19980086748A/ko not_active Ceased
- 1998-05-04 AU AU63801/98A patent/AU725621B2/en not_active Ceased
- 1998-05-04 MY MYPI98001980A patent/MY136261A/en unknown
- 1998-05-04 HU HU9801022A patent/HUP9801022A3/hu unknown
- 1998-05-04 ZA ZA9803720A patent/ZA983720B/xx unknown
- 1998-05-04 NZ NZ330359A patent/NZ330359A/en unknown
- 1998-05-06 JP JP10123230A patent/JP3010153B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HUP9801022A3 (en)	2001-10-29
HUP9801022A2 (hu)	2000-03-28
JPH10316588A (ja)	1998-12-02
ES2227773T3 (es)	2005-04-01
AU725621B2 (en)	2000-10-19
EP0880964A3 (de)	2002-07-17
MY136261A (en)	2008-09-30
EP0880964A2 (de)	1998-12-02
IL124236A (en)	2003-01-12
CA2236553C (en)	2002-10-29
JP3010153B2 (ja)	2000-02-14
DK0880964T3 (da)	2004-12-27
CA2236553A1 (en)	1998-11-05
DE69826561T2 (de)	2006-03-09
ATE277607T1 (de)	2004-10-15
TW589184B (en)	2004-06-01
US5990111A (en)	1999-11-23
PT880964E (pt)	2004-12-31
DE69826561D1 (de)	2004-11-04
AU6380198A (en)	1998-11-05
KR19980086748A (ko)	1998-12-05
EP0880964B1 (de)	2004-09-29
NZ330359A (en)	2000-06-23

Publication	Publication Date	Title
NZ517616A (en)	2002-12-20	Use of retigabin for treating neuropathic pain
IL158593A0 (en)	2004-05-12	Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
ZA983720B (en)	1999-11-04	Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy.
WO2003053383A3 (fr)	2004-01-22	Utilisation cosmetique d’au moins une hydrophobine pour le traitement des matieres keratiniques
ZA939161B (en)	1994-08-15	Wastewater treatment.
ZA9811507B (en)	2000-06-19	Combination effective for the treatment of impotence.
YU89503A (sh)	2006-05-25	Korišćenje osteopontina za lečenje i/ili prevenciju neuroloških bolesti
EP0909561A3 (de)	1999-05-06	Verwendung der Reboxetin zur Behandlung der Aufmerksamkeitsmangel/Hyperaktivität Störung
EP0930067A3 (de)	1999-09-15	Mmp inhibitoren zur behandlung von okularer angiogenesis
SG166661A1 (en)	2010-12-29	Precursor compounds
AU2001275450A1 (en)	2001-12-17	Bismuth compounds for the treatment and prevention of mucositis
AU2636602A (en)	2002-06-18	Use of sarp-1 for the treatment and/or prevention of scleroderma
ZA200004363B (en)	2002-02-25	Treatment or prevention of coccidiosis.
EP1251847A4 (de)	2004-11-10	Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
ZA200204156B (en)	2003-07-30	Water treatment.
AU2335601A (en)	2001-07-16	Treatment or prevention of diarrhea
AP2004002980A0 (en)	2004-03-31	The treatment of lipodystrophy.
ZA200103250B (en)	2001-10-25	The treatment of immunomodulatory related and other diseases or conditions.
AU1278700A (en)	2000-06-13	Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
ZA994585B (en)	2001-01-15	Treatment of water.
AU2003297522A8 (en)	2004-07-22	Bacteriophage-encoded antibacterial enzyme for the treatment and prevention of gingivitis and root surface caries
ZA994586B (en)	2001-01-15	Treatment of water.
ZA996546B (en)	2001-05-31	Treatment of water.
ZA994584B (en)	2001-01-15	Treatment of water.
ZA995993B (en)	2000-04-05	Treatment of timber poles.